NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said this week that Edison Liu and current company CSO, Analytical Technologies Klaus Lindpaintner have joined its scientific advisory board.
Liu is president and CEO of the Jackson Laboratory, he founded the Genome Institute of Singapore in 2001, and he was scientific director of the National Cancer Institute's Division of Clinical Sciences for five years.
Before joining Thermo Fisher, Lindpaintner was CSO and VP of R&D at Strategic Diagnostics, and he also previously was director of the Roche Center for Medical Genomics and global head of molecular medicine policy and external affairs for F. Hoffmana-La Roche AG.
Fluidigm said this week that Un Kwon-Casado has been promoted to the position of vice president of corporate development.
Kwon-Casado has served as director of strategic marketing at Fluidigm since October 2009. Prior to that she was vice president of healthcare equity research for Pacific Growth Equities.
Epigenomics disclosed last week that company CEO Geert Nygaard left the firm as of Sept. 30, and that Thomas Taapken has been appointed as sole member of the company's executive board, effective Oct. 1.
Taapken previously served as CFO at Epigenomics, a position he held since April 2011. He joined Epigenomics from Biotie Therapies in Finland, where he also served as CFO. He was appointed to this position in 2008, following a merger between Biotie Therapies and Elbion, where Taapken had been CFO since 2005. He has also held positions as an investment partner at Deutsche Venture Capital and Burrill & Company. Taapken also worked several years at Sanofi-Aventis.
Epigenomics also disclosed that it has promoted Uwe Staub, former senior vice president of research and development, to the position of COO.
Pressure Biosciences said in a recent filing with the US Securities and Exchange Commission that Joseph Damasio, VP of finance and administration, is leaving the company to pursue other opportunities as of Nov. 16.
Cepheid said this week that Philippe Jacon, current CEO of the Foundation of Innovative New Diagnostics (FIND), will join the company in January as executive VP of emerging markets, a new position.
In the post, he will be responsible for pursuing emerging commercial opportunities in the Asia-Pacific region, India, Eastern Europe, sub-Saharan Africa, and Latin America. He also will be responsible for the firm's High Burden Developing Country (HBDC) program. While at FIND, Jacon worked closely with Cepheid on the HBDC program.
He formerly was director general of the European Diagnostics Manufacturers Association and worldwide president of Becton Dickinson Diagnostics Systems.
Becton Dickinson announced this week that William Kozy, who currently is executive VP at the company, will also now serve as chief operating officer.
Kozy started at BD in 1974, and he has held a number of leadership posts with the company, including stints as president of BD Worldwide Injection Systems; senior VP of company operations; president of BD Diagnostics; and executive VP
Rosetta Genomics has nominated Yitzhak Peterburg to serve on the company's board of directors and has called a shareholder meeting to approve the appointment. If approved, he will be the seventh member of Rosetta Genomics' board.
Peterburg formerly was senior VP and head of Global Branded Products at Teva Pharmaceuticals, where he currently is a board member. He also was GM at Clalit Health Services, an Israeli non-government, non-profit comprehensive health services organization, and he was CEO of Soroka University Medical Center.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.